{"id":"NCT00396253","sponsor":"Genentech, Inc.","briefTitle":"A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters","officialTitle":"A Phase III, Open-Label Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis (HD) Catheters","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2006-11-06","resultsPosted":"2011-08-02","lastUpdate":"2017-01-12"},"enrollment":223,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Dysfunctional Hemodialysis Catheters"],"interventions":[{"type":"DRUG","name":"Tenecteplase","otherNames":[]}],"arms":[{"label":"Tenecteplase","type":"EXPERIMENTAL"}],"summary":"This was a Phase III, open-label study conducted at 44 centers in the United States, Canada, and Puerto Rico. 223 subjects who required hemodialysis (HD) and had a dysfunctional HD catheter were enrolled in the study.","primaryOutcome":{"measure":"Percentage of Participants Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1","timeFrame":"Visit 1 (the first hemodialysis session in which treatment was administered). BFR was measured at the beginning of hemodialysis (Baseline measurement) and at 30 minutes prior to the end of hemodialysis and at the end of hemodialysis.","effectByArm":[{"arm":"Tenecteplase","deltaMin":34.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":null,"sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":20},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":223},"commonTop":["Nausea","Headache","Hypotension","Muscle Spasms","Pruritus"]}}